Vergoeding 2014-2018 voor ATC-subgroep J05AP : Antivirale middelen voor behandeling van hcv-infecties
- Raming voor de totale Zvw-populatie
| 2014 | 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|---|
| J05AP01 Ribavirine | 185.030 | 468.570 | 443.800 | 142.830 | 86.185 |
| J05AP03 Boceprevir | 11.284 | 5.191 | . | . | . |
| J05AP05 Simeprevir (Olysio ®) | . | 14.059.800 | 1.941.300 | 247.030 | 58.035 |
| J05AP07 Daclatasvir (Daklinza ®) | . | 18.067.700 | 24.202.200 | 6.061.800 | 828.480 |
| J05AP08 Sofosbuvir (Sovaldi ®) | 1.877.300 | 63.418.600 | 42.950.600 | 11.079.800 | 2.247.900 |
| J05AP09 Dasabuvir (Exviera ®) | . | 208.180 | 423.920 | 59.635 | 4.186 |
| J05AP51 Sofosbuvir met ledipasvir (Harvoni ®) | . | 10.313.600 | 57.094.600 | 18.910.700 | 7.334.900 |
| J05AP53 Ombitasvir met paritaprevir en ritonavir (Viekirax ®) | . | 2.971.700 | 5.687.800 | 822.040 | 84.546 |
| J05AP54 Elbasvir met grazoprevir (Zepatier ®) | . | . | . | 1.622.000 | 1.138.500 |
| J05AP55 Sofosbuvir met velpatasvir (Epclusa ®) | . | . | . | 11.148.200 | 14.595.600 |
| J05AP56 Sofosbuvir met velpatasvir en voxilaprevir (Vosevi ®) | . | . | . | . | 520.870 |
| Totaal | 2.073.614 | 109.513.341 | 132.744.220 | 50.094.035 | 26.899.202 |